270 related articles for article (PubMed ID: 34871371)
1. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
4. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
7. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
Berrien-Elliott MM; Foltz JA; Russler-Germain DA; Neal CC; Tran J; Gang M; Wong P; Fisk B; Cubitt CC; Marin ND; Zhou AY; Jacobs MT; Foster M; Schappe T; McClain E; Kersting-Schadek S; Desai S; Pence P; Becker-Hapak M; Eisele J; Mosior M; Marsala L; Griffith OL; Griffith M; Khan SM; Spencer DH; DiPersio JF; Romee R; Uy GL; Abboud CN; Ghobadi A; Westervelt P; Stockerl-Goldstein K; Schroeder MA; Wan F; Lie WR; Soon-Shiong P; Petti AA; Cashen AF; Fehniger TA
Sci Transl Med; 2022 Feb; 14(633):eabm1375. PubMed ID: 35196021
[TBL] [Abstract][Full Text] [Related]
9. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
10. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.
Ahmadvand M; Barough MS; Barkhordar M; Faridfar A; Ghaderi A; Jalaeikhoo H; Rajaienejad M; Majidzadeh K; Ghavamzadeh A; Sarrami-Forooshani R
BMC Cancer; 2023 Nov; 23(1):1090. PubMed ID: 37950209
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
13. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
Shapiro RM; Birch GC; Hu G; Vergara Cadavid J; Nikiforow S; Baginska J; Ali AK; Tarannum M; Sheffer M; Abdulhamid YZ; Rambaldi B; Arihara Y; Reynolds C; Halpern MS; Rodig SJ; Cullen N; Wolff JO; Pfaff KL; Lane AA; Lindsley RC; Cutler CS; Antin JH; Ho VT; Koreth J; Gooptu M; Kim HT; Malmberg KJ; Wu CJ; Chen J; Soiffer RJ; Ritz J; Romee R
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35349491
[TBL] [Abstract][Full Text] [Related]
14. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
15. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
16. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Otegbeye F; Cooper B; Caimi P; Zamborsky K; Reese-Koc J; Hillian A; Hernandez-Collazo Y; Lee G; Boughan K; Tomlinson B; Gallogly M; Metheny L; Bajor D; Selfridge J; Saltzman J; Lazarus H; de Lima M; Wald D
Transplant Cell Ther; 2022 May; 28(5):250.e1-250.e8. PubMed ID: 35172204
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
20. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
